IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

May 17, 2024

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OCTQB: IGXT; TSX:IGX), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announced today that its Board of Directors has authorized the Company and its subsidiary to bring an application in the Québec Superior Court (Commercial Division) (the “Court”) to seek protection from creditors under the Companies’ Creditors Arrangement Act (“CCAA”) to give the Company sufficient time and breathing room to implement a review of its strategic alternatives.

Read more at globenewswire.com

Related news for (IGXT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.